I went back and re-read all the Biotech Mailbag columns written in 2008 and was amazed to see that I wrote about 65 different biotech companies this year, many of them several times.
My thanks and gratitude go out to all the readers who emailed questions and comments this year. The Biotech Mailbag would be rather anemic if it weren't for your passion and curiosity.
The Mailbag in 2008 had its share of hits and misses. I managed to please a lot of you; others couldn't stand some of the things I wrote and let me know it in no uncertain terms.
Elan (ELN) received more play in the Mailbag this year than any other stock, mainly due to my ongoing (and quite skeptical) coverage of the company's experimental Alzheimer's disease drug bapineuzumab. The "Elanians" -- followers and fans of Elan -- are a vocal bunch, for sure.I made some stock calls this year in the Mailbag. Some worked, others didn't. Readers and I had a multi-Mailbag debate over the approvability of Vanda Pharmaceuticals' (VNDA) schizophrenia drug iloperidone. Many readers were optimistic about FDA approval. I wasn't, mainly because iloperidone seemed like a "me-too" drug with poorer safety and worse side effects. In the end, the FDA chose not to approve the drug. Earlier in the year, I highlighted Middlebrook Pharmaceuticals (MBRK) because I thought an acquisition of the company would double the stock price. That takeout never happened. Bad call. I also thought that Cardiome (CRME) and its partner Astellas would be successful in getting their anti-arrhythmia drug Kynapid approved by the FDA, even through a year's worth of regulatory delays. To date, Kynapid is still not approved.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV